ARCHIVES

Q & A: NCI’s Doroshow Says Phase I Program Will Stress Correlative Studies for Small Biotech Firms

This article is from The Cancer Letter archive.

Vol. 38 No. 14 | April 6, 2012

Download PDF Visit The Full Archive

Related Articles

DCPC Advisors OK Expansion Of Science Enrichment Program, Other Concepts

November 1, 1991

Roferon A Application Marred By Mission Data, Protocol, Compliance

September 24, 1999

NCI Considering Master Agreements For Cancer Centers

August 2, 1991

Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%

June 28, 2013

Lombardi Center Officials Say New Partnership To Provide For Expansion In Services, Patients.

February 23, 2001

Tamoxifen Listed By IARC Report As Carcinogen CTRF Seeks Applicants

March 1, 1996